Axitinib (Inlyta): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Advanced Renal Cell Carcinoma

Axitinib (Inlyta) is an oral, potent and relatively selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. It primarily inhibits VEGFR-1, VEGFR-2, and VEGFR-3, thereby suppressing VEGF-driven angiogenesis, vascular permeability, and tumor blood-vessel formation. Unlike broader multikinase inhibitors such as sunitinib or sorafenib, axitinib is more specifically focused on the VEGF pathway.

In the United States, axitinib is FDA approved for advanced renal cell carcinoma (RCC) in three settings: with pembrolizumab as first-line therapy, with avelumab as first-line therapy, and as single-agent treatment after failure of one prior systemic therapy.

Key Facts

• Generic name: Axitinib
• Brand name: Inlyta
• Drug class: VEGFR tyrosine kinase inhibitor
• Major targets: VEGFR-1, VEGFR-2, VEGFR-3
• Route: Oral
• Initial US approval: 2012
• Tablet strengths: 1 mg and 5 mg
• Standard starting dose: 5 mg twice daily
• Administration: Approximately 12 hours apart
• Food: With or without food
• Potential dose escalation: 7 mg twice daily, then 10 mg twice daily in selected patients
• Dose reductions: 3 mg twice daily, then 2 mg twice daily
• First-line combinations: Pembrolizumab or avelumab
• Monotherapy indication: Advanced RCC after one prior systemic therapy
• Major toxicities: Hypertension, diarrhea, thromboembolism, hemorrhage, cardiac failure, proteinuria, hepatotoxicity, thyroid dysfunction
• Important interaction pathway: CYP3A4/5.

What Is Axitinib?

Axitinib is a small-molecule inhibitor designed to suppress signaling through the:

VEGF–VEGFR pathway.

Clear-cell RCC is strongly associated with dysregulation of angiogenesis. Loss of normal VHL signaling can lead to increased production of proangiogenic factors such as VEGF, allowing tumors to develop an extensive vascular network.

Axitinib inhibits the intracellular kinase activity of:

• VEGFR-1
• VEGFR-2
• VEGFR-3

and thereby reduces downstream signaling required for:

• Endothelial-cell proliferation
• Migration
• Vascular survival
• New blood-vessel formation
• Tumor vascularization.

What Is the Mechanism of Action of Axitinib?

1. Tumor Cells Produce VEGF

Renal cancers, particularly clear-cell RCC, may produce high levels of:

VEGF

which binds VEGF receptors on vascular endothelial cells.

2. VEGF Activates VEGFR-1, VEGFR-2, and VEGFR-3

Activation of these receptor tyrosine kinases stimulates intracellular pathways responsible for:

• Endothelial proliferation
• Migration
• Survival
• Vascular permeability
• Angiogenesis

3. Axitinib Inhibits VEGFR Kinase Activity

Axitinib binds to and inhibits the intracellular kinase domains of:

VEGFR-1, VEGFR-2, and VEGFR-3.

This prevents receptor phosphorylation and downstream VEGF signaling.

4. Angiogenesis Is Suppressed

As VEGFR signaling decreases:

• Endothelial-cell proliferation falls
• New vessel formation decreases
• Tumor vascularization is reduced

5. Tumor Growth Is Restricted

The reduction in blood supply and angiogenesis ultimately contributes to:

• Reduced tumor growth
• Reduced metastatic progression
• Tumor regression in responsive patients

The mechanism can be summarized as:

Axitinib → VEGFR-1/2/3 inhibition → reduced VEGF signaling → ↓angiogenesis and vascular support → reduced tumor growth.

What Is the Dose of Axitinib?

The recommended starting dose is:

5 mg orally twice daily

with doses administered approximately:

12 hours apart.

Axitinib may be given:

With or without food.

Treatment generally continues until:

• Disease progression
• Unacceptable toxicity.

Axitinib With Pembrolizumab

For first-line advanced RCC:

Axitinib 5 mg orally twice daily

plus:

Pembrolizumab 200 mg intravenously every 3 weeks

or:

Pembrolizumab 400 mg intravenously every 6 weeks.

When used with pembrolizumab, axitinib dose escalation above 5 mg twice daily may be considered at intervals of:

6 weeks or longer

in appropriately selected patients.

Axitinib With Avelumab

For first-line advanced RCC:

Axitinib 5 mg orally twice daily

plus:

Avelumab 800 mg intravenously every 2 weeks.

When used with avelumab, axitinib dose escalation may be considered at intervals of:

2 weeks or longer.

Axitinib as Monotherapy

For advanced RCC after failure of one prior systemic treatment:

Axitinib 5 mg orally twice daily.

How Should Axitinib Be Taken?

Axitinib should be taken:

• Approximately 12 hours apart
• At approximately the same times each day
• With or without food

Tablets should be:

Swallowed whole with a full glass of water.

What If a Dose Is Missed?

If a dose is missed:

Do not take an additional replacement dose.

Take the next dose at the:

Usual scheduled time.

If vomiting occurs after taking axitinib:

Do not take another dose to replace it.

How Are Axitinib Dose Adjustments Made?

Unlike many TKIs, axitinib can be both:

• Dose reduced
• Dose escalated

depending on tolerability.

Standard Dose

• 5 mg twice daily

Dose Escalation

For selected patients who have tolerated axitinib for at least 2 consecutive weeks without Grade >2 toxicity, remain normotensive, and are not receiving antihypertensive medication:

• First increase: 7 mg twice daily
• Second increase: 10 mg twice daily.

Dose Reduction

If toxicity requires reduction:

• First reduction: 3 mg twice daily
• Second reduction: 2 mg twice daily.

Dose Modification for Hypertension

For persistent blood pressure:

>150/100 mmHg despite antihypertensive therapy

reduce axitinib by:

One dose level.

For:

SBP >160 mmHg or DBP >105 mmHg

• Withhold axitinib
• Resume when BP is below 150/100 mmHg
• Restart at a reduced dose.

For:

Grade 4 hypertension or hypertensive crisis

axitinib should be:

Permanently discontinued.

What Are the Important Drug Interactions With Axitinib?

Axitinib is primarily metabolized through:

CYP3A4/5.

Strong CYP3A4/5 Inhibitors

Strong inhibitors can increase axitinib exposure.

Examples include:

• Ketoconazole
• Itraconazole
• Clarithromycin
• Ritonavir

These combinations should generally be:

Avoided if possible.

If unavoidable, axitinib should be reduced by approximately:

50%.

After the inhibitor is discontinued, the prior axitinib dose may generally be resumed after approximately:

3–5 inhibitor half-lives.

Strong CYP3A4/5 Inducers

Strong CYP3A4/5 inducers may reduce axitinib exposure.

Examples include:

• Rifampin
• Carbamazepine
• Phenytoin
• Phenobarbital
• St. John’s wort

Concomitant use should generally be:

Avoided.

Does Axitinib Require Renal Dose Adjustment?

Population pharmacokinetic analyses indicate that:

Mild, moderate, and severe renal impairment did not meaningfully alter axitinib pharmacokinetics.

Therefore routine starting-dose modification based solely on renal impairment is generally not required.

However, data in:

End-stage renal disease

are extremely limited.

Does Axitinib Require Hepatic Dose Adjustment?

Mild Hepatic Impairment

Child-Pugh A:

No starting-dose adjustment is required.

Moderate Hepatic Impairment

Child-Pugh B:

Reduce the starting dose by approximately:

50%.

For example:

5 mg twice daily → approximately 2 mg twice daily, with subsequent adjustment according to tolerability.

Severe Hepatic Impairment

Child-Pugh C:

Axitinib has:

Not been adequately studied.

What Is the Pharmacokinetic Profile of Axitinib?

Absorption

After a single oral dose:

Median Tmax is approximately:

2.5–4.1 hours.

Bioavailability

Mean absolute oral bioavailability is approximately:

58%.

Food Effect

Compared with overnight fasting:

• Moderate-fat meal produced about 10% lower AUC
• High-fat/high-calorie meal produced about 19% higher AUC

These changes are not considered clinically important enough to require fasting administration.

Therefore axitinib can be taken:

With or without food.

Protein Binding

Axitinib is:

>99% protein bound

primarily to:

• Albumin
• α1-acid glycoprotein.

Half-Life

The plasma half-life is approximately:

2.5–6.1 hours.

Steady state is generally expected within:

2–3 days.

Metabolism

Axitinib is metabolized predominantly by:

CYP3A4/5

with smaller contributions from:

• CYP1A2
• CYP2C19
• UGT1A1.

Elimination

Following a radiolabeled dose:

• Approximately 41% is recovered in feces
• Approximately 23% is recovered in urine.

Unchanged axitinib is not detected in urine to a meaningful degree.

What Are the Clinical Uses of Axitinib?

1. First-Line Advanced RCC With Pembrolizumab

Axitinib is FDA approved with:

Pembrolizumab

for first-line treatment of:

Advanced renal cell carcinoma.

This combination has become one of the major immunotherapy–VEGFR TKI approaches in advanced RCC.

2. First-Line Advanced RCC With Avelumab

Axitinib is FDA approved with:

Avelumab

for first-line treatment of advanced RCC.

3. Previously Treated Advanced RCC

Axitinib is also FDA approved as:

Single-agent therapy

after failure of:

One prior systemic treatment.

What Did the AXIS Trial Show?

The pivotal phase III AXIS trial compared:

Axitinib

with:

Sorafenib

in patients with previously treated metastatic RCC.

A total of:

723 patients

were randomized:

• Axitinib: 361
• Sorafenib: 362.

Progression-Free Survival

Median PFS:

• 6.7 months with axitinib
• 4.7 months with sorafenib

Hazard ratio:

0.665

95% CI:

0.544–0.812

P < 0.0001.

These results established axitinib as an effective second-line VEGFR-targeted therapy.

Overall Survival in AXIS

Updated analysis showed median OS:

• 20.1 months with axitinib
• 19.2 months with sorafenib

Hazard ratio:

0.969

P = 0.3744.

The OS difference was not statistically significant.

What Did KEYNOTE-426 Show?

The phase III KEYNOTE-426 trial established:

Pembrolizumab + axitinib

as a major first-line treatment strategy for advanced RCC.

A total of:

861 patients

were randomized to:

• Pembrolizumab + axitinib
• Sunitinib.

Initial KEYNOTE-426 Results

Median PFS was:

• 15.1 months with pembrolizumab + axitinib
• 11.1 months with sunitinib

Hazard ratio:

0.69

P < 0.001.

Objective response rate:

• 59.3%
• 35.7%.

Five-Year KEYNOTE-426 Results

Long-term follow-up confirmed durable benefit.

Median OS:

• 47.2 months with pembrolizumab + axitinib
• 40.8 months with sunitinib

Hazard ratio:

0.84

95% CI:

0.71–0.99.

Median PFS:

• 15.7 months
• 11.1 months

Hazard ratio:

0.69.

Confirmed ORR:

• 60.6%
• 39.6%.

Median duration of response:

• 23.6 months
• 15.3 months.

These long-term findings continue to support pembrolizumab + axitinib as an established first-line regimen for advanced clear-cell RCC.

What Did JAVELIN Renal 101 Show?

The phase III JAVELIN Renal 101 trial compared:

Avelumab + axitinib

with:

Sunitinib

in previously untreated advanced RCC.

A total of:

886 patients

were randomized.

Progression-Free Survival

In the overall population, updated analysis showed median PFS:

• 13.3 months with avelumab + axitinib
• 8.0 months with sunitinib

Hazard ratio:

0.69

P < 0.0001.

Final JAVELIN Renal 101 Results

With a minimum follow-up of approximately:

68 months

median OS in the overall population was:

• 44.8 months with avelumab + axitinib
• 38.9 months with sunitinib

Hazard ratio:

0.88

P = 0.0669.

The OS difference did not reach statistical significance.

However, objective response rate remained substantially higher:

• 59.7% with avelumab + axitinib
• 32.0% with sunitinib.

Is Axitinib FDA Approved?

Yes.

FDA-approved indications include:

Pembrolizumab + Axitinib

First-line treatment of:

Advanced RCC

Avelumab + Axitinib

First-line treatment of:

Advanced RCC

Axitinib Monotherapy

Treatment of advanced RCC after:

Failure of one prior systemic therapy.

What Is the Current Clinical Role of Axitinib in 2026?

Axitinib remains an important VEGFR inhibitor in advanced RCC, particularly because it can be combined effectively with immune-checkpoint inhibition.

Pembrolizumab + Axitinib

This remains an established first-line option for advanced clear-cell RCC.

The ≥5-year KEYNOTE-426 results continue to demonstrate:

• Overall-survival benefit
• Progression-free-survival benefit
• Higher response rates
• Durable responses

compared with sunitinib.

Read more: Metastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition — OncoDaily’s contemporary review of RCC treatment, including axitinib + pembrolizumab and the role of axitinib after prior therapy.

Watch more: OncoDaily discussion on first-line treatment strategies in advanced renal cell carcinoma, including VEGFR-TKI and immunotherapy combinations relevant to axitinib.

Avelumab + Axitinib

The combination remains FDA approved and produces substantial:

• PFS improvement
• Response-rate improvement

compared with sunitinib.

However, final JAVELIN Renal 101 follow-up did not demonstrate a statistically significant OS advantage.

Axitinib Monotherapy

Axitinib monotherapy retains an FDA-approved role after one prior systemic treatment, based principally on the AXIS trial.

In contemporary practice, its exact placement depends on:

• Prior immunotherapy
• Prior VEGF-targeted therapy
• Tolerability
• Patient comorbidities
• Treatment availability
• Subsequent-line sequencing considerations.

What Are the Major Side Effects of Axitinib?

Common adverse effects with axitinib monotherapy include:

• Diarrhea
• Hypertension
• Fatigue
• Reduced appetite
• Nausea
• Dysphonia
• Hand-foot syndrome
• Weight loss
• Vomiting
• Asthenia
• Constipation.

Important serious toxicities include:

• Hypertension
• Arterial thromboembolic events
• Venous thromboembolism
• Hemorrhage
• Cardiac failure
• GI perforation or fistula
• Thyroid dysfunction
• Proteinuria
• Hepatotoxicity
• Reversible posterior leukoencephalopathy syndrome
• Impaired wound healing
• Embryo-fetal toxicity.

Hypertension

Hypertension is one of the most characteristic axitinib toxicities.

In the AXIS safety population:

• Any-grade hypertension: 40%
• Grade 3–4 hypertension: 16%
• Hypertensive crisis: <1%.

Blood pressure increases may occur:

As early as 4 days after starting treatment.

Median onset was within:

The first month.

Blood pressure should be controlled before treatment begins and monitored regularly during therapy.

Arterial and Venous Thromboembolism

Axitinib has been associated with:

• Cerebrovascular events
• Myocardial infarction
• Transient ischemic attack
• Deep-vein thrombosis
• Pulmonary embolism

Patients should be monitored for symptoms suggesting arterial or venous thrombosis.

Hemorrhage

Axitinib can cause clinically significant bleeding.

Monitor for:

• Hematuria
• GI bleeding
• Epistaxis
• Hemoptysis
• Intracranial bleeding where clinically relevant.

Grade 3–4 hemorrhage generally requires:

• Treatment interruption
• Subsequent dose reduction or discontinuation depending on severity.

Cardiac Failure

Axitinib can cause:

• Reduced LVEF
• Cardiomyopathy
• Clinical heart failure

Monitor patients for:

• Dyspnea
• Peripheral edema
• Exercise intolerance
• Other signs of cardiac dysfunction.

In selected patients, LVEF assessment may be appropriate.

Proteinuria

In the controlled RCC study:

• Proteinuria occurred in 11%
• Grade 3 proteinuria occurred in 3%.

Proteinuria should be assessed:

• Before treatment
• Periodically during treatment.

For:

≥2 g protein per 24 hours

withhold axitinib until proteinuria falls below 2 g/24 hours, then resume at a reduced dose.

Hepatotoxicity

Axitinib can cause elevated liver enzymes.

As monotherapy, Grade 3–4 ALT elevations were uncommon, but hepatotoxicity becomes particularly important when axitinib is combined with:

• Pembrolizumab
• Avelumab

because Grade 3–4 ALT and AST elevations occur more frequently than with either drug alone.

Monitor:

• ALT
• AST
• Bilirubin

before treatment and periodically thereafter.

More frequent monitoring should be considered with immunotherapy combinations.

Thyroid Dysfunction

Axitinib can cause:

• Hypothyroidism
• Hyperthyroidism

Monitor thyroid function:

• Before treatment
• Periodically during treatment
• As clinically indicated.

Reversible Posterior Leukoencephalopathy Syndrome

RPLS/PRES is rare but serious.

Possible symptoms include:

• Headache
• Seizures
• Confusion
• Lethargy
• Visual disturbance
• Hypertension.

If RPLS develops:

Permanently discontinue axitinib.

Impaired Wound Healing

VEGF-pathway inhibition may impair wound healing.

Axitinib should be managed carefully around:

• Major surgery
• Significant wounds
• Procedures requiring tissue healing.

Treatment interruption may be necessary.

Embryo-Fetal Toxicity

Axitinib can cause fetal harm.

Patients of reproductive potential should receive counseling regarding:

• Pregnancy risk
• Effective contraception.

Breastfeeding is not recommended during therapy according to prescribing information.

What Monitoring Is Required?

Monitoring during axitinib therapy should include:

• Blood pressure
• ALT
• AST
• Bilirubin
• Urinalysis / urine protein
• Thyroid function
• Signs of arterial thrombosis
• Signs of venous thrombosis
• Bleeding symptoms
• Cardiac symptoms
• LVEF when clinically indicated
• Gastrointestinal symptoms suggesting perforation or fistula
• Neurologic symptoms suggesting PRES/RPLS
• Wound healing
• CYP3A4/5 drug interactions
• Pregnancy status when appropriate
• Immune-related toxicity when combined with pembrolizumab or avelumab.